Glenmark Pharmaceuticals Ltd. - Research Center
532296 GLENMARK Group (A) BSE data
Results
Statement
More
| Mar ' 23 |
Mar ' 22 |
Mar ' 21 |
Mar ' 20 |
Mar ' 19 |
Equity share capital
| 28.22 |
28.22 |
28.22 |
28.22 |
28.22 |
Share application money
Preference share capital
Reserves & surplus
| 17,849.25 |
16,710.37 |
14,781.29 |
13,198.05 |
11,913.87 |
Secured loans
| 3,156.40 |
3,670.35 |
3,625.59 |
3,573.76 |
3,134.48 |
Unsecured loans
Total
| 21,033.86 |
20,408.94 |
18,435.10 |
16,800.03 |
15,076.57 |
Gross block
| 2,674.02 |
2,643.67 |
2,503.32 |
2,282.87 |
1,972.48 |
Less : revaluation reserve
Less : accumulated depreciation
| 928.07 |
891.34 |
780.83 |
670.93 |
559.00 |
Net block
| 1,745.94 |
1,752.33 |
1,722.49 |
1,611.95 |
1,413.48 |
Capital work-in-progress
| 172.34 |
109.04 |
131.40 |
200.01 |
286.20 |
Investments
| 10,334.01 |
8,559.39 |
6,989.95 |
4,713.93 |
3,268.75 |
Current assets, loans & advances
| 12,333.63 |
12,493.73 |
11,773.68 |
12,425.71 |
12,174.27 |
Less : current liabilities & provisions
| 3,552.06 |
2,505.55 |
2,182.42 |
2,151.57 |
2,066.13 |
Total net current assets
| 8,781.57 |
9,988.19 |
9,591.26 |
10,274.14 |
10,108.14 |
Miscellaneous expenses not written
Total
| 21,033.86 |
20,408.94 |
18,435.10 |
16,800.03 |
15,076.57 |
Book value of unquoted investments
| 10,332.50 |
8,557.90 |
6,989.88 |
4,713.90 |
3,268.65 |
Market value of quoted investments
| 3,975.01 |
4,659.12 |
0.07 |
0.03 |
0.10 |
Contingent liabilities
| 3,922.95 |
3,699.68 |
4,012.99 |
4,663.26 |
3,894.11 |
Number of equity sharesoutstanding (Lacs)
| 2821.68 |
2821.68 |
2821.68 |
2821.68 |
2821.68 |